TY - JOUR
T1 - Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population
AU - Neuzillet, Yann
AU - Tillou, Xavier
AU - Mathieu, Romain
AU - Long, Jean Alexandre
AU - Gigante, Marc
AU - Paparel, Philippe
AU - Poissonnier, Laura
AU - Baumert, Hervé
AU - Escudier, Bernard
AU - Lang, Hervé
AU - Rioux-Leclercq, Nathalie
AU - Bigot, Pierre
AU - Bernhard, Jean Christophe
AU - Albiges, Laurence
AU - Bastien, Laurence
AU - Petit, Jacques
AU - Saint, Fabien
AU - Bruyere, Franck
AU - Boutin, Jean Michel
AU - Brichart, Nicolas
AU - Karam, Georges
AU - Branchereau, Julien
AU - Ferriere, Jean Marie
AU - Wallerand, Hervé
AU - Barbet, Sébastien
AU - Elkentaoui, Hicham
AU - Hubert, Jacques
AU - Feuillu, Benoit
AU - Theveniaud, Pierre Etienne
AU - Villers, Arnauld
AU - Zini, Laurent
AU - Descazeaux, Aurélien
AU - Roupret, Morgan
AU - Barrou, Benoit
AU - Fehri, Karim
AU - Lebret, Thierry
AU - Tostain, Jacques
AU - Terrier, Jean Etienne
AU - Terrier, Nicolas
AU - Martin, Lucille
AU - Dugardin, Fabrice
AU - Galliot, Ismaël
AU - Staerman, Frédéric
AU - Azemar, Marie Dominique
AU - Irani, Jacques
AU - Tisserand, Baptiste
AU - Timsit, Marc Olivier
AU - Sallusto, Federico
AU - Rischmann, Pascal
AU - Guy, Laurent
AU - Valeri, Antoine
AU - Deruelle, Charles
AU - Azzouzi, Abdel Rahmne
AU - Chautard, Denis
AU - Mejean, Arnaud
AU - Salomon, Laurent
AU - Rigaud, Jérôme
AU - Pfister, Christian
AU - Soulié, Michel
AU - Kleinclauss, Franois
AU - Badet, Lionel
AU - Patard, Jean Jacques
PY - 2011/8/1
Y1 - 2011/8/1
N2 - Background: Patients with end-stage renal disease (ESRD) are at risk of developing renal tumours. Objective: Compare clinical, pathologic, and outcome features of renal cell carcinomas (RCCs) in ESRD patients and in patients from the general population. Design, setting, and participants: Twenty-four French university departments of urology participated in this retrospective study. Intervention: All patients were treated according to current European Association of Urology guidelines. Measurements: Age, sex, symptoms, tumour staging and grading, histologic subtype, and outcome were recorded in a unique database. Categoric and continuous variables were compared by using chi-square and student statistical analyses. Cancer-specific survival (CSS) was assessed by Kaplan-Meier and Cox methods. Results and limitations: The study included 1250 RCC patients: 303 with ESRD and 947 from the general population. In the ESRD patients, age at diagnosis was younger (55 ± 12 yr vs 62 ± 12 yr); mean tumour size was smaller (3.7 ± 2.6 cm vs 7.3 ± 3.8 cm); asymptomatic (87% vs 44%), low-grade (68% vs 42%), and papillary tumours were more frequent (37% vs 7%); and poor performance status (PS; 24% vs 37%) and advanced T categories (≥3) were more rare (10% vs 42%). Consistently, nodal invasion (3% vs 12%) and distant metastases (2% vs 15%) occurred less frequently in ESRD patients. After a median follow-up of 33 mo (range: 1-299 mo), 13 ESRD patients (4.3%), and 261 general population patients (27.6%) had died from cancer. In univariate analysis, histologic subtype, symptoms at diagnosis, poor PS, advanced TNM stage, high Fuhrman grade, large tumour size, and non-ESRD diagnosis context were adverse predictors for survival. However, only PS, TNM stage, and Fuhrman grade remained independent CSS predictors in multivariate analysis. The limitation of this study is related to the retrospective design. Conclusions: RCC arising in native kidneys of ESRD patients seems to exhibit many favourable clinical, pathologic, and outcome features compared with those diagnosed in patients from the general population.
AB - Background: Patients with end-stage renal disease (ESRD) are at risk of developing renal tumours. Objective: Compare clinical, pathologic, and outcome features of renal cell carcinomas (RCCs) in ESRD patients and in patients from the general population. Design, setting, and participants: Twenty-four French university departments of urology participated in this retrospective study. Intervention: All patients were treated according to current European Association of Urology guidelines. Measurements: Age, sex, symptoms, tumour staging and grading, histologic subtype, and outcome were recorded in a unique database. Categoric and continuous variables were compared by using chi-square and student statistical analyses. Cancer-specific survival (CSS) was assessed by Kaplan-Meier and Cox methods. Results and limitations: The study included 1250 RCC patients: 303 with ESRD and 947 from the general population. In the ESRD patients, age at diagnosis was younger (55 ± 12 yr vs 62 ± 12 yr); mean tumour size was smaller (3.7 ± 2.6 cm vs 7.3 ± 3.8 cm); asymptomatic (87% vs 44%), low-grade (68% vs 42%), and papillary tumours were more frequent (37% vs 7%); and poor performance status (PS; 24% vs 37%) and advanced T categories (≥3) were more rare (10% vs 42%). Consistently, nodal invasion (3% vs 12%) and distant metastases (2% vs 15%) occurred less frequently in ESRD patients. After a median follow-up of 33 mo (range: 1-299 mo), 13 ESRD patients (4.3%), and 261 general population patients (27.6%) had died from cancer. In univariate analysis, histologic subtype, symptoms at diagnosis, poor PS, advanced TNM stage, high Fuhrman grade, large tumour size, and non-ESRD diagnosis context were adverse predictors for survival. However, only PS, TNM stage, and Fuhrman grade remained independent CSS predictors in multivariate analysis. The limitation of this study is related to the retrospective design. Conclusions: RCC arising in native kidneys of ESRD patients seems to exhibit many favourable clinical, pathologic, and outcome features compared with those diagnosed in patients from the general population.
KW - End-stage renal disease
KW - Pathology
KW - Prognosis
KW - Renal cell carcinoma
KW - Transplantation
UR - http://www.scopus.com/inward/record.url?scp=79959536662&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2011.02.035
DO - 10.1016/j.eururo.2011.02.035
M3 - Article
C2 - 21377780
AN - SCOPUS:79959536662
SN - 0302-2838
VL - 60
SP - 366
EP - 373
JO - European Urology
JF - European Urology
IS - 2
ER -